+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Growth Hormone Treatment in Growth Hormone-Sufficient and -Insufficient Children with Intrauterine Growth Retardation/Russell-Silver Syndrome

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Fifty-eight short prepubertal children with IUGR received GH treatment (mean dose: 28 IU/m<sup>2</sup>/week) for a mean (SEM) period of time of 3.4 (0.13) years (range 1–4 years). They were subdivided according to their GH response to a pharmacological test. Twenty-six were GH insufficient (GHI) (group 1) and 32 were non-GHI (group 2). At the commencement of GH therapy mean chronological age was 6.1 (0.4) years in both groups, mean height SDS (SEM) was –3.5 (0.2) in group 1 and –3.6 (0.2) in group 2, mean growth velocity (GV) SDS (SEM) was –1.9 (0.3) in group 1 and –0.3 (0.2) in group 2. GH therapy induced significant growth acceleration throughout the follow-up period without any significant differences between the two groups. GV SDS (SEM) increased to +3.0 (0.5) in group 1 and to +3.7 (0.4) in group 2 (p < 0.05 compared to baseline) during the first year of therapy. Subsequently, the growth-promoting effects of GH therapy diminished with time but GV remained significantly higher than baseline. This growth enhancement produced a significant rise in height SDS (SEM) reaching –1.4 (0.2) in group 1 and –1.7 (0.2) in group 2 after 4 years. In conclusion, our data did not show any significant differences in the growth response to GH therapy between GH-sufficient and -insufficient IUGR children who were only distinguishable by their GH secretion. This indicates that the decision to treat a short IUGR child with GH therapy should not be based upon the GH response to a provocative test.

          Related collections

          Most cited references 3

          • Record: found
          • Abstract: not found
          • Article: not found

          Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited

           R Rosenfeld (1995)
            • Record: found
            • Abstract: not found
            • Article: not found

            Spontaneous 24-hour growth hormone profiles in prepubertal small for gestational age children

              • Record: found
              • Abstract: not found
              • Article: not found

              Dose-dependent catch-up growth after 2 years of growth hormone treatment in intrauterine growth-retarded children. Belgian and French Pediatric Clinics and Sanofi-Choay (France)

               P Chatelain (1994)

                Author and article information

                Horm Res Paediatr
                Hormone Research in Paediatrics
                S. Karger AG
                July 1998
                09 July 1998
                : 50
                : 1
                : 22-27
                Department of Paediatric Endocrinology, Great Ormond Street Hospital for Children, London, UK
                23196 Horm Res 1998;50:22–27
                © 1998 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                Page count
                Pages: 6
                Original Paper


                Comment on this article